Publications
Selected publications since 2013. For full list, please visit pubmed.org.
2019
Büküm N., Novotná E., Morell, A., Hofman J., Wsól V., 2019. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chem Biol Interact, 302, 101-107.
2018
2017
Hulova D., Breiterova K., Zemanova L., Siatka T., Safratova M., Vaneckova N., Hostalkova A., Cahlikova L., 2017. AKR1C3 inhibitory potency of naturally-occurring amaryllidaceae alkaloids of different structural types. Nat Prod Commun, 12(2), 245-246.
Zemanova L., Kirubakan P., Pato I.H., Stambergova H., Vondrasek J., 2017. The identification of new substrates of human DHRS7 by molecular modeling and in vitro testing. Int J Biol Macromol, 105(Pt.1). 171-182.
Novotná E., Waisser K., Kuneš J., Palát K., Skálová L., Szotáková B., Buchta V., Stolaříková J., Ulmann V., Pávová M., Weber J., Komrsková J., Hašková P., Vokřál I., Wsól V., 2017. Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Arch Pharm (Weinheim), 350(8): e1700020.
Malátková P., Skarka A., Musilova K., Wsol V., 2017. Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes. Chem Biol Interact. in press. doi: 10.1016/j.cbi.2017.03.006
Soukup O., Winder M., Killi U.K., Wsol V., Jun D., Kuca K., Tobin G., 2017. Acetylcholinesterase inhibitors and drugs acting on muscarinic receptors - potential crosstalk of cholinergic mechanism during pharmacological treatment. Curr Neuropharmacol. 15(4): 637-653.
2016
Malátková P., Kanavi M., Nobilis M., Wsol V., 2016. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 258:153-158.
Malátková P., Sokolová S., Chocholoušová Havlíková L., Wsól V., 2016. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases. Biochem Pharmacol. 109:83-90.
Hintzpeter J., Seliger J.M., Hofman J., Martin H.J., Wsol V., Maser E, 2016. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance. Toxicol Appl Pharmacol. 293:21-9.
Lundová T., Štambergova H., Zemanová L., Svobodová M., Havránková J., Šafr M., Wsól V., 2016. Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. Mol Cell Biochem. 411(1-2):35-42.
Štambergová H., Zemanova L., Lundova T., Malčeková B., Skarka A., Šafr M., Wsol V., 2016. Human DHRS7, promising enzyme in metabolism of steroids and retinoids?. J Steroid Biochem Mol Biol. 155(Pt.A):112-9.
2015
Zemanova L., Hofman J., Novotná E., Musilek K., Lundova T., Havrankova J., Hostalkova A., Chlebek J., Cahlikova L., Wsol V., 2015. Flavones inhibit the activity of AKR1B10, a promising therapetic target for cancer treatment. J Nat Prod. 75(11):2666-74.
Andrys R., Zemanová L., Lenco J., Bilkova Z., Wsol V., 2015. Carbonyl-reducing enzymes as targets of a drug-immobilised affinity carrier. Chem Biol Interact. 234:169-77.
Hofman J., Skarka A., Havrankova J., Wsol V., 2015. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochem Pharmacol. 96(3):168-78.
Lundová T., Zemanová L., Malčeková B., Skarka A., Štambergová H., Havránková J., Šafr M., Wsól V., 2015. Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 234:178-87.
2014
Hofman J., Malčeková B., Skarka A, Novotná E., Wsol V., 2014. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol. 278(3):238-48.
Krátký M., Vinšová J., Novotná E., Stolaříková J., 2014. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase. European Journal of Pharmaceutical Sciences, 53:1-9.
Malátková P., Havlíková L., Wsól V., 2014. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact., 220C:241-247.
Malátková P., Wsól V., 2014. Carbonyl reduction pathways in drug metabolism. Drug Metabolism Reviews, 2014, 46(1):96-123.
Malíř F., Ostrý V., Pfohl-Leszkowicz A., Novotná E., 2014. Ochratoxin A: developmental and reproductive toxicity - an overview. Birth Defects Res B Develop Reprod Toxicol. 98(6):493-502.
Skarka A., Škarydová L., Štambergová H., Wsól V. Purification and reconstitution of human membrane-bound DHRS7 (SDR34C1) from Sf9 cells. Protein Expression and Purification, 95:44-49.
Škarydová L., Tomanová R., Havlíková L., Stambergová H., Solich P., Wsól V., 2014. Deeper insight into the reducing biotransformation of bupropion in the human liver. Drug Metab Pharmacokinet., 28(2):177-84.
Škarydová L., Hofman J., Chlebek J., Havránková J., Kosanová K., Skarka A., Hošťálková A., Plucha T., Cahlíková L., Wsol V., 2014. Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem Mol Biol. 143:250-8.
Štambergová H., Škarydová Lucie, Dunford, J.E., Wsól, V., 2014. Biochemical properties of human dehydrogenase reductase (SDR family) member 7. Chem-Biological Interact., 207:52-57.
2013
Skarydova L., Andrys R., Holubova L., Stambergova H., Knavova J., Wsol V., Bilkova Z., 2013. Efficient isolation of carbonyl-reducing enzymes using affinity approach with anticancer drug oracin as a specific ligand. J Separation Sci, 36(7):1176-84.
Skarydova L., Zverinova M., Stambergova H., Wsol V., 2013. A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK. Drug Metab Lett., 6(3), 174-181.
Hartmanova T., Tambor V., Lenco J., Staab-Weijnitz C.A., Maser E., Wsól V., 2013. S-Nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity. Chem Biol Interact., 202(1-3):136-145.
Skarydova L., Nobilis M., Wsól V., 2013. Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica, 43(4):346-354.